Abstract
Mounting evidence suggests that copper may influence the progression of Alzheimers disease by reducing clearance of the amyloid beta protein (Aß) from the brain. We propose that Aβ is cleared from the brain by tagging along with cholesterol/ApoE in traversing the BBB, with subsequent incorporation into HDL for delivery of the toxin to the liver. It is suggested that either ABC-A1 or LRP, or both are involved in Aβ transport across the BBB, as well as normal cholesterol efflux. We have previously shown that addition of only 0.12 PPM copper (one-tenth the Environmental Protection Agency Human consumption limits) to distilled water was sufficient to precipitate the accumulation of Aß in the brains of cholesterol-fed rabbits. Here we show that in a setting of elevated cholesterol levels, overproduced Aβ is cleared to the blood and can simultaneously be identified in the liver if copper ion is absent from the animals drinking water, but if trace levels copper (0.12 PPM) are added to the drinking water Aβ accumulates in the brain, while the levels in the liver are greatly reduced.
Keywords: AD-like neuropathology, amyloid-beta, liver copper, ABCA1, LRP
Current Alzheimer Research
Title: Cholesterol Metabolism and Brain Amyloidosis: Evidence for a Role of Copper in the Clearance of A β Through the Liver
Volume: 4 Issue: 2
Author(s): D. Larry Sparks
Affiliation:
Keywords: AD-like neuropathology, amyloid-beta, liver copper, ABCA1, LRP
Abstract: Mounting evidence suggests that copper may influence the progression of Alzheimers disease by reducing clearance of the amyloid beta protein (Aß) from the brain. We propose that Aβ is cleared from the brain by tagging along with cholesterol/ApoE in traversing the BBB, with subsequent incorporation into HDL for delivery of the toxin to the liver. It is suggested that either ABC-A1 or LRP, or both are involved in Aβ transport across the BBB, as well as normal cholesterol efflux. We have previously shown that addition of only 0.12 PPM copper (one-tenth the Environmental Protection Agency Human consumption limits) to distilled water was sufficient to precipitate the accumulation of Aß in the brains of cholesterol-fed rabbits. Here we show that in a setting of elevated cholesterol levels, overproduced Aβ is cleared to the blood and can simultaneously be identified in the liver if copper ion is absent from the animals drinking water, but if trace levels copper (0.12 PPM) are added to the drinking water Aβ accumulates in the brain, while the levels in the liver are greatly reduced.
Export Options
About this article
Cite this article as:
Larry Sparks D., Cholesterol Metabolism and Brain Amyloidosis: Evidence for a Role of Copper in the Clearance of A β Through the Liver, Current Alzheimer Research 2007; 4 (2) . https://dx.doi.org/10.2174/156720507780362119
DOI https://dx.doi.org/10.2174/156720507780362119 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
How Should We Deal with Missing Data in Clinical Trials Involving Alzheimers Disease Patients?
Current Alzheimer Research Ethical Issues in Managing the Pregnancies of Patients with Schizophrenia
Current Women`s Health Reviews Dual Cross-Talk between Nitric Oxide and D-Serine in Astrocytes and Neurons in the Brain
Central Nervous System Agents in Medicinal Chemistry Targeted Blood-to-Brain Drug Delivery – 10 Key Development Criteria
Current Pharmaceutical Biotechnology Commentary: The Effects of Psychological Stress on Microglial Cells in the Brain
CNS & Neurological Disorders - Drug Targets CA125: An Increasingly Promising Biomarker of Heart Failure
Current Pharmaceutical Design New Insights in Prolactin Releasing Peptide (Prrp) in the Brain
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Discovery of Novel Lead in the Group of N-substituted Piperazine Ether Derivatives with Potential Histamine H<sub>3</sub> Receptor Activity
Medicinal Chemistry Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets Editorial (Hot Topic: Mitochondrion: An Organelle More and More Implication in New Processes)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology Heteroaromatization with 4-Phenyldiazenyl-1-naphthol. Part IV: Synthesis of Some New Heterocyclic Compounds with Potential Biological Activity
Current Organic Synthesis Introduction from the Guest Editor: The Many Facets of Heme Oxygenase
Current Neurovascular Research Vascular Risk Factors, Vascular Diseases, and Imaging Findings in a Hospital-based Cohort of Mild Cognitive Impairment Types
Current Alzheimer Research A Computational Molecular Docking Studies on the Tryparedoxin Peroxidase of <i>Leishmania donovani</i> Responsible for Visceral Leishmaniasis in Human
Letters in Drug Design & Discovery Outer Surface Proteins of Borrelia: Peerless Immune Evasion Tools
Current Protein & Peptide Science Ivabradine: The Hope for a Good Treatment of Ischemic Heart Disease
Current Medicinal Chemistry Immunophenotype of Vitamin D Receptor Polymorphism Associated to Risk of HIV-1 Infection and Rate of Disease Progression
Current HIV Research Review on Triggered Liposomal Drug Delivery with a Focus on Ultrasound
Current Cancer Drug Targets Myocardial Energetics in Left Ventricular Hypertrophy
Current Cardiology Reviews